Inhibition of Bfl-1 with N-aryl maleimides

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 22, 2010, Pages 6560-6564

  Cashman, John R ^a   MacDonald, Mary ^a   Ghirmai, Senait ^a   Okolotowicz, Karl J ^a   Sergienko, Eduard ^b   Brown, Brock ^b   Garcia, Xochella ^b   Zhai, Dayong ^b   Dahl, Russell ^b   Reed, John C ^b  

^a HUMAN BIOMOLECULAR RESEARCH INSTITUTE   (United States)

^b BURNHAM INSTITUTE   (United States)

Author keywords

Anti cancer agents; Bfl 1 inhibitors; High throughput screening; N Aryl maleimides

Indexed keywords

3,4 DICHLORO 1 (3,4 DICHLOROPHENYL) 1H PYROLE 2,5 DIONE; AMINE; ANTINEOPLASTIC AGENT; BCL2 RELATED PROTEIN A1; MALEIMIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; DRUG SYNTHESIS; ELECTRON; HIGH THROUGHPUT SCREENING; IC 50; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION;

HUMANS; MALEIMIDES; PROTO-ONCOGENE PROTEINS C-BCL-2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77958043876     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.09.046     Document Type: Article

References (21)

1. J.C. Reed Nat. Rev. Drug Discov. 1 2002 111
2. R. Beroukhim, C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J.S. Boehm, J. Dobson, M. Urashima, K.T. Mc Henry, R.M. Pinchback, A.H. Ligon, Y.J. Cho, L. Haery, H. Greulich, M. Reich, W. Winckler, M.S. Lawrence, B.A. Weir, K.E. Tanaka, D.Y. Chiang, A.J. Bass, A. Loo, C. Hoffman, J. Prensner, T. Liefeld, Q. Gao, D. Yecies, S. Signoretti, E. Maher, F.J. Kaye, H. Sasaki, J.E. Tepper, J.A. Fletcher, J. Tabernero, J. Baselga, M.S. Tsao, F. Demichelis, M.A. Rubin, P.A. Janne, M.J. Daly, C. Nucera, R.L. Levine, B.L. Ebert, S. Gabriel, A.K. Rustgi, C.R. Antonescu, M. Ladanyi, A. Letai, L.A. Garraway, M. Loda, D.G. Beer, L.D. True, A. Okamoto, S.L. Pomeroy, S. Singer, T.R. Golub, E.S. Lander, G. Getz, W.R. Sellers, and M. Meyerson Nature 463 2010 899
3. R.W. Johnstone, A.A. Ruefli, and S.W. Lowe Cell 108 2002 153
4. L. Chen, S.N. Willis, A. Wei, B.J. Smith, J.I. Fletcher, M.G. Hinds, P.M. Colman, C.L. Day, J.M. Adams, and D.C.S. Huang Mol. Cell 17 2005 393
5. T. Kuwana, L. Bouchier-Hayes, J.E. Chipuk, C. Bonzon, B.A. Sullivan, D.R. Green, and D.D. Newmeyer Mol. Cell 7 2005 525
6. M. Vogler, D. Dinsdale, M.J.S. Dyer, and G.M. Cohen Cell Death Differ. 16 2009 360
7. S. Kitada, M. Leone, S. Sareth, D. Zhai, J.C. Reed, and M. Pellecchia J. Med. Chem. 2003 46
8. M. Leone, D. Zhai, S. Sareth, S. Kitada, J.C. Reed, and M. Pellecchia Cancer Res. 63 2003 8118
9. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, M.K. Joseph, S. Kitada, S.J. Korsmeyer, A.R. Kunzer, A. Letai, C. Li, M.J. Mitten, D.G. Nettesheim, S. Ng, P.M. Nimmer, J.M. O'Connor, A. Oleksijew, A.M. Petros, J.C. Reed, W. Shen, S.K. Tahir, C.B. Thompson, K.J. Tomaselli, B. Wang, M.D. Wendy, H. Zhang, S.W. Fesik, and S.H. Rosenberg Nature 435 2005 677
10. M. Pellecchia, and J.C. Reed Curr. Pharm. Des. 10 2004 1387
11. J. Wei, S. Kitada, M.F. Rega, J.L. Stebbins, D. Zhai, J. Cellitti, H. Yuan, A. Emdadi, R. Dahl, Z. Zhang, L. Yang, J.C. Reed, and M. Pellecchia J. Med. Chem. 52 2009 4511
12. A. Degterev, A. Lugovskoy, M. Cardone, B. Mulley, G. Wagner, T. Mitchison, and J. Yuan Nat. Cell Biol. 3 2001 173
13. D. Zhai, C. Jin, A.C. Satterthwait, and J.C. Reed Cell Death Differ. 13 2006 1419
14. S.P. Holmgreen, D.C.S. Huang, J.M. Adams, and S. Cory Cell Death Differ. 6 1999 525
15. H.H. Lee, H. Dadgostar, Q. Cheng, J. Shu, and G. Cheng Proc. Natl. Acad. Sci. U.S.A. 96 1999 9136
16. A.B. Werner, E. de Bries, S.W.G. Tait, I. Bontjer, and J. Borst J. Biol. Chem. 277 2002 22781
17. Day, C. L.; Chen, L.; Richardson, S. J.; Harrison, P. J.; Huang, D. C. S.; Hings, M. G. J. Biol. Chem. 2005, 280. High-throughput FP assay: Chemical inhibitors were dissolved in 10% DMSO at 100 μM stock concentration. From this solution, 4 μL were incubated with 8 μL of Bfl-1 working solution (7.4 nM GST-Bfl-1 fusion protein in 25 mM Bis-Tris pH 7.0, 1 mM TCEP, 0.005% Tween 20) at room temperature away from direct sunlight in 384-well black plates (Greiner Bio-One, Monroe, NC). After 1 h, FITC-Bid BH3 peptide (8 μL of 5.6 nM in 25 mM Bis-Tris pH 7.0, 1 mM TCEP, 0.005% Tween 20) was added, and plates were incubated at room temperature away from direct sunlight. Fluorescence polarization was measured using an Analyst GT plate reader (Molecular Devices, Inc., Sunnyvale, CA) using fluorescein filters (excitation filter 485 nm, emission filter 530 nm, dichroic mirror # 505 nm). Data analysis was done using CBIS software (ChemInnovations, Inc., San Diego, CA). Dose-response confirmation: Chemical inhibitors were serially diluted in DMSO then in water so final concentration was in 10% DMSO. Ten concentrations of each compound were used. Each inhibitor (4 μL) was transferred to 384-well black plates (Greiner Bio-One, Monroe, NC) followed by GST-Bfl-1 solution described above (8 μL). Plates were incubated for 1 h at 4 °C. FITC-Bid BH3 peptide solution described above (8 μL) was added, and plates were incubated for 4 h at room temperature. Fluorescence polarization was measured at described above. Data analysis was performed using sigmoidal dose-response equation through non-linear regression.
18. 50 data in the tables) can be found at: http://graphpad.com/help/prism5/prism5help.html? usingstatistical-analyses-step-by-s.htm.
19. D. Zhai, C. Jin, C.-w. Shiau, S. Kitada, A.C. Satterthwait, and J.C. Reed Mol. Cancer Ther. 7 2008 1639
20. L. Hanaineh-Abdelnour, S. Bayyuk, and R. Theodorie Tetrahedron 55 1999 11859
21. http://www.ncbi.nlm.nih.gov/pccompound.